Federal officials are resuming enforcement of regulations that dictate how pharmaceutical products can be advertised to consumers, the Trump administration said on Sept. 9, as President Donald Trump signed a new executive order.
The Food and Drug Administration (FDA) is restarting its enforcement of regulations that prohibit pharmaceutical ads from creating a “misleading impression” and require them to present a “fair balance of information,” a senior administration official told reporters on a call.
